METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers bring to these four metabolic research peptides.
What is semaglutide?
Semaglutide is a 31-amino-acid synthetic analogue of glucagon-like peptide-1 (GLP-1), a gut hormone that tells the pancreas to secrete insulin after eating and tells the brain that a meal is sufficient. Its key engineering change — a C18 fatty di-acid side chain that binds to albumin — extends the half-life to approximately one week, enabling once-weekly dosing. It is an FDA-approved prescription medicine for type 2 diabetes, chronic weight management, and cardiovascular-risk reduction [4][5].
What is semaglutide used for?
FDA-approved indications include type 2 diabetes mellitus, chronic weight management in adults with overweight or obesity, and reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight/obesity (without diabetes). A 2025 approval added metabolic steatohepatitis. In the SELECT trial, semaglutide reduced cardiovascular events by 20% relative to placebo (HR 0.80) in 17,604 adults with established CVD and overweight/obesity [3]. In STEP 1, mean body-weight loss was -14.9% at 68 weeks [4]. Use outside approved indications is off-label.
How does semaglutide work?
Semaglutide mimics native GLP-1 at the GLP-1 receptor. That receptor is expressed on pancreatic beta cells (which secrete more insulin in a glucose-dependent way), pancreatic alpha cells (which reduce inappropriate glucagon), gastric smooth muscle (slowing emptying), and in the hypothalamus and brainstem (reducing appetite). Rodent mechanistic studies showed the weight effect is primarily central — semaglutide accessed appetite-regulating circuits in the arcuate nucleus and area postrema, reducing food intake and modifying food preference without lowering energy expenditure [6].
How does semaglutide work for weight loss?
The weight effect is primarily through appetite suppression in the central nervous system. Semaglutide activates anorexigenic (appetite-reducing) neurons in the hypothalamic arcuate nucleus and inhibits orexigenic (hunger-promoting) neurons, reducing food intake and changing food preferences toward less-calorie-dense options [6]. Slower gastric emptying extends the sense of fullness. The net effect in STEP 1 was -14.9% mean body weight at 68 weeks versus -2.4% with placebo in adults with overweight or obesity without diabetes [4]. Weight regain occurs after stopping — this is documented in the STEP extension data [5].
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously agonizes both the GIP receptor and the GLP-1 receptor — making it the first FDA-approved dual incretin agonist. Built on a GIP-based backbone with a C20 fatty-diacid arm for albumin binding and once-weekly dosing, it is approved for type 2 diabetes mellitus and chronic weight management [8]. It is not the same as semaglutide; it activates an additional receptor and has produced larger weight losses in head-to-head comparison [1].
How does tirzepatide work?
By engaging both the GIPR and GLP-1R simultaneously, tirzepatide amplifies the incretin response beyond what GLP-1 agonism alone provides. The GLP-1R arm drives glucose-dependent insulin secretion, glucagon suppression, gastric slowing, and central appetite suppression. The GIPR arm adds additional insulinotropic effects and may improve the tolerability of the GLP-1 effects on appetite [8]. The combination produced superior weight loss versus semaglutide in SURMOUNT-5 (-20.2% vs -13.7% at 72 weeks, P<0.001) [1] and superior HbA1c reduction versus semaglutide 1 mg in SURPASS-2 [11].
What does tirzepatide do in the body?
Tirzepatide reduces body weight by suppressing appetite through GLP-1 receptor signaling in the brain and GIP receptor signaling in adipose tissue and appetite circuits. It lowers blood glucose by stimulating insulin secretion (glucose-dependently) and suppressing glucagon. It slows gastric emptying, which contributes to satiety and can cause nausea. In SURMOUNT-1, mean weight losses were -15.0/-19.5/-20.9% at 5/10/15 mg respectively versus -3.1% with placebo over 72 weeks [10]. It is used in clinical practice for type 2 diabetes and obesity.
What is tirzepatide used for?
FDA-approved indications: type 2 diabetes mellitus (approved May 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition (approved November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. The StatPearls reference chapter notes that weight-loss efficacy, while now approved, was initially an off-label observation from the diabetes trials; the compound is not approved for type 1 diabetes [8].
What does retatrutide do?
Retatrutide is an investigational triple agonist — it activates the GIP, GLP-1, and glucagon receptors simultaneously with one molecule. The GLP-1 and GIP arms suppress appetite and improve glucose handling; the glucagon receptor arm raises energy expenditure through thermogenic mechanisms and promotes hepatic lipid mobilization. Phase 2 data showed mean weight loss of -24.2% at 48 weeks at the 12 mg dose in adults with obesity [15], and -82.4% relative reduction in liver fat in people with metabolic liver disease [14]. Retatrutide is not FDA-approved; it remains in Phase 3 trials as of mid-2026.
How does retatrutide work?
Retatrutide engages three metabolic receptors simultaneously. Cryo-EM structural work resolved its binding to GLP-1R, GIPR, and GCGR complexes and quantified relative potencies: approximately 8.9× more potent at GIPR than native GIP, 0.3× at GCGR, and 0.4× at GLP-1R versus endogenous hormones [13]. The glucagon receptor arm drives cAMP/PKA signaling in adipose and liver tissue, raising energy expenditure — the mechanism believed to account for the weight-loss step-change beyond the dual-agonist class. A 2025 review characterizes this as the key pharmacological distinction [12].
Is retatrutide FDA approved?
No. As of mid-2026, retatrutide is investigational and has not been approved by the FDA or any regulatory agency. It is in Phase 3 clinical trials (the TRIUMPH program, Eli Lilly). The evidence cited on this desk comes from Phase 2 trials conducted under regulated clinical conditions [15][16]. Material sold through gray-market channels as "research retatrutide" has no verified identity, purity, or sterility, and the FDA issued warning letters to vendors in 2025 citing Federal FD&C Act violations [15].
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), bearing a trans-3-hexenoic acid N-terminal modification that resists DPP-IV cleavage and extends plasma stability. It binds the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile growth-hormone release and subsequent IGF-1 production [18][20]. It is FDA-approved (November 2010) for reducing excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy — that is its only approved indication.
What does tesamorelin do?
In its approved indication, tesamorelin reduces visceral adipose tissue by stimulating the body's own pulsatile GH secretion, which raises IGF-1 and drives preferential lipolysis in visceral fat depots. A 2026 meta-analysis of five RCTs found it reduced visceral fat by a mean of 27.71 cm², trunk fat by 1.18 kg, and hepatic fat fraction by 4.28%, while increasing lean mass by 1.42 kg, all in HIV-associated lipodystrophy populations [17]. In a 52-week program, reductions were sustained at -18% VAT versus baseline, but visceral fat reaccumulated after discontinuation [21]. It is WADA-prohibited under S2.
How does tesamorelin work?
Tesamorelin activates the GHRH receptor on anterior-pituitary somatotroph cells, triggering the Gs/adenylyl-cyclase/cAMP/PKA cascade and stimulating endogenous GH synthesis and pulsatile release. The GH released drives hepatic IGF-1 production; GH and IGF-1 together activate hormone-sensitive lipase in visceral adipocytes, preferentially mobilizing visceral fat. In healthy men (n=13) over two weeks, tesamorelin increased overnight GH by +0.5 µg/L and IGF-1 by 181 µg/L without significantly affecting glucose or insulin sensitivity [20]. Because it amplifies the body's own pulsatile rhythm rather than supplying exogenous GH, its metabolic profile differs from recombinant growth hormone.
Will tesamorelin help me lose belly fat?
In the specific population in which it was studied — HIV-infected adults with antiretroviral-related lipodystrophy — it reduced visceral fat significantly (mean -42 cm² in a JAMA RCT [19], mean -27.71 cm² across a 2026 meta-analysis of five RCTs [17]). Outside that population, generalizability is mechanistically plausible but not established by large RCTs. Pivotal trials enrolled HIV-positive adults on antiretroviral therapy; applying those findings to other populations is extrapolation. Crucially, visceral fat reaccumulated after stopping [21]. Use outside the approved indication is off-label. This page reports evidence; it does not offer medical advice.